Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14th, at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceutica ...

Company Overview - scPharmaceuticals Inc. is a pharmaceutical company focused on revolutionizing cardiorenal healthcare through patient-centric innovations [3][4] - The company's mission is to advance cardiorenal care with innovative, integrated treatments that address unmet patient needs [3] Upcoming Events - Management will host a conference call and audio webcast on May 14, 2025, at 4:30 p.m. ET to discuss the financial results for the first quarter of 2025 and provide a business update [1] - Registration for the conference call can be completed through a direct registration link, and the live webcast will be accessible on the company's website [2]